Last reviewed · How we verify
NCT05667155
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Status unknown
Phase 1
Last updated 6 February 2023
What this trial tests
Phase 1 trial testing CB dualCAR-NK19/70 in B-cell Non Hodgkin Lymphoma in 48 participants. Status unknown.
Timeline
15 December 2022
Primary endpoint
1 January 2025
1 January 2025
30 December 2025
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 15 December 2022 |
| Primary completion | 1 January 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- CB dualCAR-NK19/70 — full drug profile →
Conditions studied
- B-cell Non Hodgkin Lymphoma — all drugs for B-cell Non Hodgkin Lymphoma →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Adults 18 to 75, any sex, with B-cell Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the safety and efficacy of cord blood-derived CAR-NK cells targeting CD19/CD70 in patients with B-cell non-Hodgkin's lymphoma
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w -
Development of NK cell-based cancer immunotherapies through receptor engineering.
Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x -
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w -
The clinical landscape of CAR NK cells.
Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8 -
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
Zhang B, Yang M, Zhang W, Liu N, et al · · 2024 · cited 50× · PMID 38221520 · DOI 10.1038/s41419-024-06438-7 -
Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Zhang Y, Zhou W, Yang J, Yang J, et al · · 2023 · cited 40× · PMID 37563648 · DOI 10.1186/s40164-023-00431-0 -
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, et al · · 2023 · cited 32× · PMID 37330575 · DOI 10.1186/s40364-023-00501-9 -
Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.
Li C, Yu X, Han X, Lian C, et al · · 2024 · cited 31× · PMID 39280627 · DOI 10.1016/j.isci.2024.110750
Verify or expand the search:
- PubMed search for NCT05667155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06707259 — Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL · Phase 1 · recruiting
- NCT06392477 — A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki · Phase 1 · recruiting
- NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
- NCT05991388 — A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma · Phase 2, PHASE3 · recruiting
- NCT05702853 — Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL · Phase 1, PHASE2 · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05667155 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 6 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing